$750 Million Settlement reached in Whistleblower case with GlaxoSmithKline

Settlement Amount: 

A settlement has been reached in a whistleblower class action lawsuit brought against GlaxoSmithKline who is accused of  improperly manufacturing drugs and selling adulterated drugs.

The settlement includes a criminal fine and forfeiture totaling $150 million and a $600 million civil settlement. The whistleblower will receive  $96 million of the settlement.

Filed in 2004, the whistleblower lawsuit alleged that GlaxoSmithKline was selling tainted drugs under false pretenses. The medicines, made at a Glaxo plant in Cidra, Puerto Rico, were misidentified as a result of product mix-ups, according to papers filed in federal court in Boston. The affected drugs included the antidepressant Paxil CR and the diabetes treatment Avandamet.

If you have a similar case please fill out the form below or email mail@whistleblowerinstitute.com or call: 619-452–1218


If you or someone you know experienced a similar situation or any other wrongdoing within a corporation you should contact mail@whistleblowerinstitute.com or call: 619-452–1218

Go to top